Paradigm Biocapital Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,574,048	Closed	-$142M	–	31
2026 Q1	$142M	Buy	+3,574,048	New	+$91.4M	2.9%	11

Paradigm Biocapital Advisors's CNTA Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 3,574,048 shares — an estimated $142M sold.

Paradigm Biocapital Advisors first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $142M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Paradigm Biocapital Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paradigm Biocapital Advisors sold 3,574,048 Centessa Pharmaceuticals shares in Q2 2026, an estimated $142M.
Paradigm Biocapital Advisors first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Paradigm Biocapital Advisors's Centessa Pharmaceuticals position peaked at $142M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.